News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Boehringer Ingelheim Corporation and Eli Lilly and Company Release: Phase III Safety and Efficacy Data of Trajenta® (linagliptin) in Elderly People With Type 2 Diabetes Published in The Lancet
August 15, 2013
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Get the latest biotech news where you want it. Sign up for the
free GenePool newsletter
today!
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
Eli Lilly and Company
Boehringer Ingelheim
MORE ON THIS TOPIC
IN PARTNERSHIP WITH PII
Hit Me With Your Best Shot: Understanding Autoinjectors and Combination Drug Delivery Systems
October 2, 2025
·
1 min read
·
BioSpace Insights
Podcast
M&A Picks Up, Walmsley Moves On, Pfizer’s MFN Deal and Hope for Huntington’s
October 1, 2025
·
2 min read
·
Heather McKenzie
Opinion
The Urgent Need To Redefine the Future of UK Biotech
October 1, 2025
·
6 min read
·
Kerstin Papenfuss
Obesity
Metsera’s Obesity Drug Shows ‘Very Encouraging’ Mid-Stage Efficacy, Supporting Pfizer’s $4.9B Bet
September 30, 2025
·
2 min read
·
Tristan Manalac
